Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Histopathological Analysis of Adipose-Derived Mesenchymal Stem Cells and Their Osteogenic Derivatives in Promoting Bone Regeneration in a Model of Fracture Nonunion.

Maslennikov S., Danukalo M., Isachenko M., Avramenko Y., Holovakha M., Kolesnyk Y.

Randomized Controlled Trial with a reported sample of 5 on Cartilage Damage, published in Med Princ Pract (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Med Princ Pract (2026)
Country
Switzerland
Reported sample size
5
Source database
PubMed
PMID
42172169
DOI
10.1159/000552577

Abstract (original English)

Objective To perform a histopathological analysis of the effects of mesenchymal stem cells (MSCs) and their osteogenically differentiated derivatives (Dif-MSCs) on reparative processes in bone tissue using an experimental model of fracture nonunion. Subjects and methods Fifteen male rabbits aged 3 months were randomly assigned to three groups: control with induced femoral nonunion (n = 5), nonunion treated with adipose-derived MSCs (n = 5), and nonunion treated with Dif-MSCs (n = 5). MSCs were isolated from lipoaspirate, cultured to passage 3, and differentiated osteogenically for 4 weeks. A 5-mm bone defect was created surgically, and cells were injected into the defect zone on day 7. Animals were euthanized at 6 weeks postinjection. Bone specimens underwent fixation, decalcification, histological staining (hematoxylin-eosin and Van Gieson), and quantitative analysis of osteoblasts and osteocytes using ImageJ. Statistical analysis included one-way ANOVA and Welch's t test. Results Macroscopic and histological evaluation revealed a gradation in regeneration: control group showed predominant fibrous tissue with immature bone and inflammation; MSCs group exhibited fibrocartilaginous callus with immature bone, bone marrow formation, and increased osteoblasts (52.0 ± 16.2 per 10 HPF vs. control 28.6 ± 7.0, p = 0.032); Dif-MSCs group demonstrated mature lamellar bone, organized oste

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research